COVID-19疫苗在日本针对感染的有效性:VENUS研究的检测阴性设计研究
该检测阴性研究利用日本四市町村≥20岁居民2021年7月1日至9月30日的COVID-19检测数据,纳入530例阳性与15650例阴性结果,评估Delta变异株占优势期间疫苗针对感染的有效性。结果显示第二剂后0-13天VE为85.2%,≥14天为79.6%,第二剂后14-34天VE最高为89.1%。结论确认了COVID-19疫苗尤其是两剂次在日本Delta变异株占优势期间针对感染的高真实世界有效性。
要点
- 第一剂后0-13天VE为4.1%(95%CI -36.5-32.6),≥14天为45.2%(95%CI 13.4-65.3)。
- 第二剂后0-13天VE为85.2%(95%CI 69.9-92.7),≥14天为79.6%(95%CI 72.6-84.8)。
- 第二剂后14-34天VE最高,为89.1%(95%CI 80.5-93.9)。
核心结论
- 确认了COVID-19疫苗尤其是两剂次在日本Delta变异株占优势期间针对感染的高真实世界有效性。
研究设计与样本
- 检测阴性研究,纳入日本四个市町村≥20岁居民,检测时间为2021年7月1日至9月30日。
- 通过医疗索赔数据提取COVID-19检测数据,接种状态通过预防接种记录系统数据确认。
- 确诊病例通过国家COVID-19系统Health Center Real-time Information-sharing System on COVID-19数据识别。
- 采用逻辑回归分析估计不同接种状态下检测阳性的比值比,VE计算为(1-比值比)×100%。
- 共纳入530例阳性结果和15650例阴性结果。
主要发现
- 调整后未区分厂家的VE:第一剂后0-13天为4.1%(95%CI -36.5-32.6),第一剂后≥14天为45.2%(95%CI 13.4-65.3)。
- 调整后未区分厂家的VE:第二剂后0-13天为85.2%(95%CI 69.9-92.7),第二剂后≥14天为79.6%(95%CI 72.6-84.8)。
- 第二剂后14-34天VE最高,为89.1%(95%CI 80.5-93.9)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the effectiveness of coronavirus disease 2019 (COVID-19) vaccines is a crucial public health concern, evidence from Western Pacific countries is limited, including Japan. This study aimed to estimate the COVID-19 vaccines effectiveness (VE) against infection during the Delta variant predominance (July-September 2021) in Japan. METHODS: We performed a test-negative study using COVID-19 test data of ≥20-year-old residents in four municipalities who were tested in medical institutions between July 1 and September 30, 2021. We extracted COVID-19 test data from healthcare claims data, and the vaccination status at the testing date was ascertained using the Vaccination Record System data. Confirmed positive cases were identified using data from the national system for COVID-19, Health Center Real-time Information-sharing System on COVID-19. Logistic regression analyses were conducted to estimate the odds of testing positive according to vaccination status. VE was calculated as (1 - odds ratio) × 100%. RESULTS: This study included 530 positive and 15,650 negative results. Adjusted manufacturer-unspecified VE was 4.1% (95% confidence interval [CI], -36.5-32.6) at 0-13 days after the first dose, 45.2% (95% CI, 13.4-65.3) at ≥14 days after the first dose, 85.2% (95% CI, 69.9-92.7) at 0-13 days after the second dose, and 79.6% (95% CI, 72.6-84.8) at ≥14 days after the second dose. In addition, the VE after the second dose was highest at 14-34 days after the dose (VE, 89.1%; 95% CI, 80.5-93.9). CONCLUSIONS: High real-world effectiveness of COVID-19 vaccines, especially two doses, against infection during the Delta variant predominance in Japan was confirmed.
引用
- Tamada Y, Takeuchi K, Kusama T, et al. Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative study from the VENUS study. Vaccine. 2023. PMID: 37487845. doi:10.1016/j.vaccine.2023.07.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。